Blog

Single Cell Genome Sequencing Market Growth Factor and Business Opportunity

Overview

Separating a single cell and multiplying and analyzing genes within that cell constitutes single cell genome sequencing. Individual cells can vary significantly in size, protein levels, and released RNA transcripts, therefore sequencing a single cell is critical. These differences might provide crucial information about medical research, embryonic cell biology, immunotherapy, molecular genetics, and neuroscience, among other fields. Single-cell analysis allows researchers to get a deeper look at individual cells’ gene expression in order to understand how they operate in complex tissues.

High-throughput sequence of individual cells is achieved using kits and devices based on technology frameworks such as Next Generation Sequencing (NGS), polymerase chain reaction (PCR), quantitative polymerase chain reaction (qPCR), and others. With a better knowledge of genomes and more genomic research, single cell sequencing has advanced dramatically, allowing researchers to track down the source of many chronic diseases.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2059

Drivers

Single cell genome sequencing is one of the most concentrated areas of study for finding a treatment for chronic diseases like cancer since it can aid in the observation of the tumor microenvironment. Cancer is one of the most common non-communicable diseases and the second largest cause of death globally, as per the World Health Organization (WHO). As per a 2012 study by the International Agency for Research on Cancer (IARC), about 14.1 million new cases of cancer were recorded in 2012, with approximately 8.8 million deaths and approximately 32.6 million individuals suffering from cancer.

The adoption of single cell genomic sequencing for improving studies in order to detect cellular level alterations in cancer cells is predicted to rise with the emergence of new medicines for cancer therapy such as customized medicine.

In addition, the use of single cell genomic sequencing in various illnesses, such as immune system disorders and contagious diseases, is a significant driver of market development. As per the Centers for Disease Control and Prevention’s 2017 Vital Signs, about 54.4 million individuals in the U.S. suffer with arthritis, accounting for 25% of the population. Rheumatoid arthritis, the most common autoimmune disease, accounts for a major proportion of global arthritis prevalence.

The global single cell genome sequencing market is projected to continue to expand due to advancements in sequencing technology. For a variety of applications, particularly single cell genomic sequencing, PCR and next-generation sequencing are quickly becoming the favored technologies. In 2017, Oxford Nanopore released two sequencing kits—one for direct cDNA analysis and the other for PCR cDNA analysis—that are simple to use and deliver findings in less time and at a lower cost.

To Get Instant Access, Purchase Report Here (Flat US $2000 OFF)@ https://www.coherentmarketinsights.com/promo/buynow/2059

The global single cell genome sequencing market is projected to develop due to several agreements between commercial firms and academic and research organizations. In 2015, three single cell genomics institutes were established in Sweden, Australia, and the United States, with the goal of facilitating single cell genome sequencing research and development. Monash University, the University of Melbourne, the University of Newcastle, the Hudson Institute of Medical Research, and Fluidigm Corporation collaborated to establish the facility in Australia.

Regional Analysis

Over the forecast period, North America is projected to dominate the global single cell genome sequencing market. The U.S. has a high rate of many forms of cancer. As per the American Cancer Society, cancer is the second biggest cause of death in 2018, behind cardiovascular disease. According to the research, about 1.7 million new instances of cancer would be diagnosed worldwide, with around half a million fatalities.

Many academic institutes and commercial firms use single cell genome sequencing to identify alterations at the gene level in single cells, which might lead to possible treatments and access to create new medications.

Furthermore, significant competitors offering cutting-edge technologies like NGS and qPCR, as well as substantial commercial and university research investment, are present in the U.S., which is projected to boost the global single cell genome sequencing market expansion.

Competitive Landscape

Major companies contributing in the global single cell genome sequencing market are QIAGEN, F. Hoffmann-La Roche Ltd., Inc., Thermo Fisher Scientific, Fludigim Corporation, Illumina, Inc., Pacific Biosciences, Oxford Nanopore Technologies, BGI, Novogene, 10x Genomics, and Bio-Rad Laboratories.

To expand their market share, companies are focusing on new product releases and partnerships. Illumina introduced the iSeq 100t, a semiconductor-based sequencing device that combines sequencing-by-synthesis chemicals with CMOS detection technology in January 2018.

QIAGEN released QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit in June 2018, introducing a new set of reagents that allow the most precise microbial community characterization from complicated microbiome samples and are utilized for single cell sequencing.

Illumina Inc. and Thermo Fisher Scientific Inc. signed a trade deal in January 2018 under which Illumina may offer Ion AmpliSeq technology to scientists using Illumina’s next-generation sequencing (NGS) systems.

The Illumina Bio-Rad Single-Cell Sequencing Solution was introduced in 2017 by Illumina Inc. and Bio-Rad Laboratories, Inc. It is the first single-cell analytic approach based on next-generation sequencing (NGS), allowing researchers to examine the role of single cells in tissue function, disease development, and clinical course.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028).

Preeclampsia is formerly known as toxemia. Preeclampsia occurs when women have high blood pressure and possibly protein in urine during pregnancy or after delivery. Preeclampsia may result in damage to the kidneys, liver, lung, heart, or eyes, and may cause a stroke or other brain injury. Preeclampsia can lead to eclampsia, a serious condition that can have health risks for both mother and baby and in rare cases can even cause death. If preeclampsia leads to seizures, then women have eclampsia. Symptoms of preeclampsia include persistent headache, abnormal swelling in hands and face, sudden weight gain, changes in vision, and pain in the right upper abdomen. The only cure for preeclampsia is to give birth. Even after delivery, symptoms of preeclampsia can last 6 weeks or more.

Market Dynamics

Key players in the market are focusing on growth strategies such as agreements, collaborations, and product launches, which are expected to drive the market growth during the forecast period. For instance, in February 2016, Diabetomics, Inc., a privately-held global medical diagnostics company, announced that the company had entered into a licensing and distribution agreement for a clinical test with BD (Becton, Dickinson and Company), a leading global medical technology company to conduct a newly developed pregnancy specific metabolic assay for the early detection of preeclampsia and gestational diabetes. In March 2015, Siemens Healthineers AG launched two new advanced urine testing solutions for the U.S. central laboratories, namely, the CLINITEK Novus Automated Urine Chemistry Analyzer and the CLINITEK AUWi PRO Automated Urine Workstation.

Request For PDF: https://www.coherentmarketinsights.com/insight/request-pdf/4606

Increasing prevalence of preeclampsia is expected to drive the market growth during the forecast period.

Increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in the developed and developing nations.

Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Buy This Premium Report: https://www.coherentmarketinsights.com/insight/buy-now/4606

Key Players

Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

Clear Aligners Market 2021-2027: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service Forecast

Clear Aligners Market – by Material Type (Polyurethane Plastic, Polyethylene Terephthalate Glycol (PETG), Poly-vinyl Chloride (PVC), and Others), by Age Group (Children, and Adults), By End User (Hospitals, and Dental Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook and Opportunity Analysis, 2018 – 2026

Market Overview:

Clear aligners are clear plastic orthodontic appliances that are a clear, transparent cover for traditional braces, made to replace the traditional metal braces that were fitted to the teeth. These clear aligners have grown increasingly more popular over recent years and their popularity is likely to continue to grow as more teenagers begin to opt for this type of treatment as a way to straighten their teeth and improve their smiles. Clear aligners are a less invasive form of treatment, which means that patients are not obliged to wear the braces at all times. The clear aligners come in a range of styles and users should be able to find one to suit their own needs and budget. They can be fitted in either only over the front teeth or over both molars. The most popular treatment for adults is the Invisalign option, but there are also a growing number of specialists who now offer the treatment for teenagers and young adults as well.

Get Sample Report Here  

Competitive Landscape:

Major players operating in the global clear aligners market include eXceed, Rocky Mountain Orthodontics, Great Lakes Dental Technologies, Henry Schein, Inc., Danaher Corporation, Straumann Group, SmileDirectClub, Dentsply Sirona, Inc., DynaFlex, and Align Technology, Inc.

Key Market Drivers:

The increasing incidence of dental issues in the world is the main factor that is estimated to boost the growth of the global clear aligners market. For instance, according to World Health Organization, the oral disease affects more than 3.5 billion individuals in the world. Moreover, increasing investment in the healthcare sector along with new product launches by several key market players are estimated to enhance the growth of the market. For instance, in September 2018, Dentsply Sirona Inc. launched a clear aligner called SureSmile Aligner at Dental Meeting in Orlando.

Covid-19 Impact Analysis:

The COVID-19 pandemic had a very negative effect on the growth of the global clear aligners market, owing to the degrading economic and social condition all over the globe, along with several side effects that happened after getting affected by the SaRS-CoV-2 virus. For instance, in March 2020, American Dental Association (ADA), recommended that dental practices should be postponed until 6th April 2020. This recommendation was again updated on 1st April 2020, where ADA advised that dental offices should remain closed to all patients and only emergency and urgent procedures can be performed toll 30th April 2020. As a result of this easy access to dental care significantly decreased.

Key Takeaways:

The global clear aligners market size was estimated at US$ 1,789.2 million in 2017 and is projected to exhibit a CAGR of 17.0% over the estimated market period (2018 – 2026), owing to the rising incidence of dental problems in the world. For instance, according to Oral Health Foundation, around 31% of all individuals in the UK suffer from tooth decay.

North America is expected to hold a major share of the global clear aligners market, owing to the increasing prevalence of dental issues in the region along with the high investment in the dental healthcare sector, and the high presence of dentists and orthodontists in the U.S. For instance, according to American Dental Association, more than 10 million Americans suffer from misaligned jaws.

The Asia Pacific is estimated to witness significant growth in the global clear aligners market, owing to the prevalence of misaligned jaws and other dental issues in the region, along with the high presence of dentists. For instance, according to Indian National Health Profile, more than 270,000 dentists are registered with the Dental Council of India (DCI). Moreover, the presence of key market players in the region is assessed to create propulsion in the market.

Oncology Nutrition Market Analysis With Latest Trends

Cancer is a group of diseases involving abnormal cell growth with the potential to spread or invade in other parts of the body. These cells are called as malignant cells or tumor cells. Oncology is the branch of medicine, which deals with prevention, diagnosis, and treatment of cancer or tumor.

The nutrition of the cancer patients during or after the treatment is termed as oncology nutrition. Proper nutrition is required for a patient suffering from cancer or is undergoing cancer treatment. Furthermore, such nutrition provides strength to fight illness and offers endurance against the after effects of the treatment.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1954

According to the nutritionists some foods that must include diet of cancer patients are milk and dairy products, eggs, meat, poultry, fish, tofu, fruits, vegetables, bread, grain, cereal products, and others. Futthermore, high fat and calorie food is recommended by doctors for cancer patients to prevent weight loss during the treatment.

Proper nutrition provides more energy and improves the quality of life by managing the side effects of the cancer treatment and also helps in speeding up the recovery of the patient. Furthermore, it helps in healing wounds after chemotherapy and other treatments.

Oncology Nutrition Market Drivers:-

Launch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.

These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch of new ready to eat products are expected to fuel growth of the oncology nutrition market.

Collaborations of key players to increase awareness for nutrition of cancer patients is also expected to drive growth of the oncology nutrition market. For instance, in 2017, Celgene Corporation, a U.S based biotechnology company, collaborated with Savor Health, which offers cancer patients expert dietary solutions.

Celgene Corporation collaborated with Savor Health to be a part of their awareness program ‘Cooking. Comfort. Care’ to increase awareness of importance of nutritional food for pancreatic cancer patients. Such campaigns that create awareness about nutritional food for cancer patients are expected to significantly contribute to growth of the oncology nutrition market.

According to a study conducted by National Cancer Institute in 2018, around 15,112,098 people in U.S. were diagnosed with cancer in 2015, whereas in 2018 around 17 million new cases of cancer were recorded. High prevalence of cancer is expected to boost the oncology nutrition market growth.

Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1954

However, high cost of oncology nutrition products is expected to restrain the oncology nutrition market growth. For instance, Nutricomp Energy HP by B. Braun Melsungen AG costs more than US$ 8898 which most people cannot afford. Thus high cost of nutritional products for cancer patients is expected to restrain the growth of oncology nutrition market.

Oncology Nutrition Market Regional Analysis:-

North America is expected to dominate the global oncology nutrition market due to launch of new oncology nutrition products by key players. For instance, in 2005, Millennium Biotechnologies, a research based nutraceutical company, launched Resurgex nutritional supplement. This supplement is designed to support immune support and increase energy in cancer patients.

Thus launch of nutritional supplements by key players to enhance and strengthen the immune system as well meet all the nutritional needs of cancer patients is expected to boost growth of the oncology nutrition market.

Asia Pacific oncology nutrition market is expected to witness growth due to increasing awareness campaigns for nutrition of cancer patients. For instance, Singapore Cancer society will be organizing their awareness campaign – Gastric Cancer Awareness 2018, in August 2018.

This campaign mainly focuses on the importance of maintaining good nutrition during and after gastric cancer treatment. Such awareness campaigns are expected to fuel growth of the oncology nutrition market.

Oncology Nutrition Market Key Drivers:-

Key players operating in the oncology nutrition market include Danone, Nestle S.A., B. Braun Melsungen AG, Abbott Laboratories, Fresenius Kabi AG, Mead Johnson & Company, LLC., Meiji Holdings Co. Ltd., Hormel Foods Corporation, Global health products Inc., and Victus.

Oncology Nutrition Market Taxonomy:-

By Cancer Type:-

  • Breast Cancer
  • Liver Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Blood Cancer
  • Esophageal Cancer
  • Head & Neck Cancer
  • Stomach & Gastrointestinal Cancer
  • Others

By Distribution Channel:-

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By region:-

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

Equine Healthcare Market Growth Analysis And Future Outlook

Equine Healthcare refers to the activities and practices aimed for the maintenance of horses. Equine healthcare offers the veterinary services intended for treating horses to enhance their quality of life, develop quality animal food and increase lifespan. The total equine population is directly proportional to the quality of equine healthcare. Equine healthcare includes a number of activities including diagnosis, therapies and supplements for maintaining internal health of horses. The diagnostic products help detect bacteria, viruses and antibodies, therapeutic products helps to treat disease through vaccination and supplement products helps in maintaining specific requirements.

High return on investment and rise in genotypic analyzers is expected to lead the market expansion

Equine veterinary practice is expected to be a high overhead owing to prevent the rising diseases like influenza virus, herpes virus, west nile virus and encephalomyelitis, where the cost for global vaccination is estimated to be around 30 million dollars by the Euro Surveillance Journal in 2016. Rising investments and popularity in alternative forms of gambling like horse racing, online gaming, betting, competitive riding, high return on investment and leisure is expected to drive the global equine healthcare market. The growth and rising demand for gestation diagnosis products, increasing urine test kits, ultrasound devices and supplement products will boost the global equine healthcare market. Additionally, the growing initiatives by equine healthcare organizations to develop drugs for various diseases is expected to give impetus to the equine healthcare market. The non-invasive test kits are largely preferred by the veterinarians owing to the easy usage and affordability.

Request PDF Brochure Of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/835

Rising demand for equine diagnostic products is expected to boost equine healthcare market

The global equine healthcare market is segmented on the basis of diagnostic products, therapeutic products, supplementary products and geography. 

On the basis of diagnostic products, the global equine healthcare market is segmented into:

  • Pregnancy and Gestation Diagnostic
  • Urine Test Kits
  • Ultrasound Devices
  • Genotyping Analysis
  • Breed Quality Analyzers
  • Semen Quality Analyzers
  • Genetic Disease Identification Products

On the basis of therapeutic products, the global equine healthcare market is segmented into:

  • Dopamine Agonists
  • Vaccines
  • Anti-Bacterial
  • Anti-Protozoal
  • Anti-Viral
  • Laxatives
  • Anti-Inflammatory

On the basis of supplement products, the global equine healthcare market is segmented into:

  • Performance Supplements
  • Proteins and Amino Acids
  • Electrolytes
  • Vitamins
  • Others
  • Protection Supplement
  • Protection Products
  • Prosthetics

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/835

Asia Pacific market is expected to show positive growth owing to the import of quality of quality breeds and their maintenance

Regional segmentation of the equine healthcare market by Coherent Market Insights comprises of North America, Europe, Asia Pacific, Latin America, Middle East and Africa. According to the study conducted by the American Horse Council in 2004, U.S. has 9.2 million horses with $39 billion direct economic impact. Also, a total 22,849 horses were imported into the U.S. in 2013, thereby increasing the demand of equine healthcare in North America. The Australian market is among the leading horse breeding countries of Asia Pacific, hence contributing to the drastically increasing demand for healthcare products in Asia Pacific. Additionally, the maintenance of race-horse breeds by the rising investments from China by specific supplements, therapeutic and protection products drive the growth of Asia Pacific market.

Animal-health innovation driven acquisition broadens global equine healthcare market

Key players operating the equine healthcare market include Affymetrix Inc., Boehringer Ingelheim, Merck, Bayer Health Care and Elanco Animal Health. The agreement of Sanofi with Bayer equine health to launch a variety of products to prevent gastric ulcer syndrome, westnile virus, equine influenza and rabies in horses. The launch of updated equine influenza vaccine ProteqFlu by Merial broadens the portfolio of leading products. Other prominent Vendors include Vetoquinol, Novartis Animal Health, Ceva Holdings and Signostics.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com